The online version of this article (doi:10.1186/1471-2261-14-192) contains supplementary material, which is available to authorized users.
Yan Zhang, Jun Liu contributed equally to this work.
The authors declare that they have no competing interests.
ZY and LJ completed the project, analyzed the data, and wrote the manuscript. LJ-J and TY established the study, interpreted the data, and contributed to reviewing/editing the manuscript. LS, XR-X, and SJ contributed to assay and analyzing the data. All authors read and approved the final manuscript.
The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been confirmed as a major factor regulating cholesterol homeostasis and has low-density lipoprotein receptor (LDLR) independent effects. In addition, the pathogenesis of acute myocardial infarction (AMI) involves lipids alteration and other acute phase responses. It remains unknown whether the PCSK9 expression is influenced by the impact of AMI. The present study aimed to investigate the changes of PCSK9 concentration using AMI rat model.
AMI (n = 6-8 at each time point) or sham operated (n = 6) adult male rats model were used. Whole blood and liver tissue were collected at 1, 3, 6, 9, 12, 24, 48, and 96 hour (h) post infarction. The plasma PCSK9 concentration was measured by ELISA and lipid profiles were measured by enzymatic assay. The liver mRNA levels of PCSK9, LDLR, sterol response element binding protein-2 (SREBP-2) and hepatocyte nuclear factor 1α (HNF1α) were measured by quantitative real-time PCR.
The plasma PCSK9 concentration was increased from 12 h to 96 h (P < 0.05 vs. control). Paralleled with the enhanced plasma PCSK9 concentration, the hepatic PCSK9 mRNA expression was up-regulated by 2.2-fold at 12 h and 4.1-fold at 24 h. Hepatic mRNA levels of LDLR, SREBP-2 and HNF1α were all increased and lipid profiles underwent great changes at this acute period.
We firstly demonstrated that PCSK9 was transiently up-regulated in the acute period of AMI, which is also driven by transcriptional factors, SREBP-2 and HNF1α, suggesting that the role of PCSK9 in myocardial injury may be needed further study.
Homer VM, Marais AD, Charlton F, Laurie AD, Hurndell N, Scott R, Mangili F, Sullivan DR, Barter PJ, Rye KA, George PM, Lambert G: Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis. 2008, 196: 659-666. 10.1016/j.atherosclerosis.2007.07.022. CrossRefPubMed
Wu NQ, Guo YL, Xu RX, Liu J, Zhu CG, Jiang LX, Li JJ: Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs. Clin Lab. 2013, 59: 901-907. PubMed
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004, 364: 937-952. 10.1016/S0140-6736(04)17018-9. CrossRefPubMed
Liu J, Guo YL, Xu RX, Li JJ: Rapid effects of different lipid-lowering drugs on PCSK9 in humans. Clin Lipidol. 2013, 8: 519-524. 10.2217/clp.13.55. CrossRef
Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G: Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis. 2010, 213: 632-636. 10.1016/j.atherosclerosis.2010.09.027. CrossRefPubMed
Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sébille V, Mahé PJ, Bach K, Masson D, Lagrost L, Costet P, Asehnoune K, Cariou B: Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab. 2013, 98: E732-E736. 10.1210/jc.2012-4236. CrossRefPubMed
Chen SN, Ballantyne CM, Gotto AM, Tan Y, Willerson JT, Marian AJ: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005, 45: 1611-1619. 10.1016/j.jacc.2005.01.051. CrossRefPubMedPubMedCentral
Duan HF, Wang H, Yi J, Liu HJ, Zhang QW, Li LB, Zhang T, Lu Y, Wu CT, Wang LS: Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther. 2007, 18: 1119-1128. 10.1089/hum.2007.036. CrossRefPubMed
Li JJ: Inflammation in coronary artery diseases. Chin Med J (Engl). 2011, 124: 3568-3575.
Blancke F, Claeys MJ, Jorens P, Vermeiren G, Bosmans J, Wuyts FL, Vrints CJ: Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediat Inflamm. 2005, 2005: 385-389. 10.1155/MI.2005.385. CrossRef
Yavuz MT, Yavuz O, Yazici M, Guler S, Ozhan H, Albayrak S, Coskun A: Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis inpatients with severe coronary stenosis. Scand J Clin Lab Invest. 2006, 66: 523-534. 10.1080/00365510600931114. CrossRefPubMed
Li JJ, Wang HR, Huang CX, Xue JL, Li GS: Enhanced response of blood monocytes to C-reactive protein in patients with unstable angina. Clin Chim Acta. 2004, 352: 127-133. CrossRef
Zhu XY, Zhang ZL, Li P, Liang WY, Feng XR, Liu ML: Shenyuan, an extract of American Ginseng and Corydalis Tuber formula, attenuates cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and oxidative stress in a porcine model of acute myocardial infarction. J Ethnopharmacol. 2013, 150: 672-681. 10.1016/j.jep.2013.09.044. CrossRefPubMed
Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL: Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012, 220: 381-386. 10.1016/j.atherosclerosis.2011.11.026. CrossRefPubMed
Berti V, Sciagrà R, Acampa W, Ricci F, Cerisano G, Gallicchio R, Vigorito C, Pupi A, Cuocolo A: Relationship between infarct size and severity measured by gated SPECT and long-term left ventricular remodelling after acute myocardial infarction. Eur J Nucl Med Mol Imaging. 2011, 38: 1124-1131. 10.1007/s00259-011-1739-7. CrossRefPubMed
Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS: Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). Am J Cardiol. 2013, 111: 506-509. 10.1016/j.amjcard.2012.10.037. CrossRefPubMed
Ferrières J, Cambou JP, Guéret P, Boutalbi Y, Lablanche JM, Hanania G, Genès N, Cantet C, Danchin N: Effect of early initiation of statins on survival in patients with acute myocardial infarction (the USIC 2000 Registry). Am J Cardiol. 2005, 95: 486-489. 10.1016/j.amjcard.2004.10.016. CrossRefPubMed
- Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat
- BioMed Central
Neu im Fachgebiet Kardiologie
Mail Icon II